Protocol No.: EA2192

APOLLO: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2, or PALB2 Mutation
Principal Investigator
Daboul, Nour
Phase
II
Age Group
Adult
Applicable Disease Site
Gastrointestinal Cancers
Participating Institution
Mary Babb Randolph Cancer Center
Contacts
Sabrina Rexroad, RN
Research Nurse
Nnennaya Opara
Clinical Research Specialist
Phone: +1 681-342-1000
Meg Zafiris
Research Specialist

View on ClinicalTrials.gov